Clinical experience with oral versus intravenous vitamin K for warfarin reversal (CME)

Transfusion

Volumn 53, Issue 3, 2013, Pages 491-498

  Meehan, Robert ^a   Tavares, Maria ^a   Sweeney, Joseph ^a  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHYTOMENADIONE; VITAMIN K GROUP; WARFARIN;

ADULT; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; MEDICAL RECORD; MULTIPLE LINEAR REGRESSION ANALYSIS; PRESCRIPTION; RECIPIENT;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; VITAMIN K; WARFARIN;

EID: 84874945921     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03755.x     Document Type: Article

References (40)

1. Link KP,. The discovery of dicumarol and its sequels. Circulation 1959; 19: 97-107.
2. Butt HR, Allen EV, Bollman JL,. A preparation from spoiled sweet clover which prolongs coagulation and prothrombin time of the blood: preliminary reports of experimental and clinical studies. Mayo Clin Proc 1941; 16: 388-95.
3. Hirsh J, Guyatt G, Albers GW, Harrington R, Schunemann HJ,. ACCP Evidence based clinical practice guidelines. Chest 2008; 133: 71S-109S.
4. Wysowski DK, Nourjah P, Swartz L,. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Int Med 2007; 167: 1414-9.
5. Budnitz DS, Pollock DA, Weldenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL,. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 2006; 296: 1858-66.
6. van Walraven C, Oake N, Wells PS Forster AJ,. Burden of potentially avoidable anticoagulant-associated hemorrhagic and thromboembolic events in the elderly. Chest 2007; 131: 1508-15.
7. Prothrombin time standardization: report of the expert panel on anticoagulant control. The International Committee on Thrombin and Hematology. Thromb Haemost 1983; 42: 1073-114.
8. Hermans J, van den Besselaar AM, Loeliger EA, van der Veld EA,. A collaborative calibration study of reference materials for thromboplastins. Thromb Haemost 1983; 50: 712-7.
9. Kirkwood TB,. Calibration of reference thromboplastins and standardization of the prothrombin time ratio. Thromb Haemost 1983; 49: 238-44.
10. Kim YK, Nieuwlaat R, Connolly SJ, Schulman S, Meijer K, Raju N, Daatz S, Eikelboom JW,. Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study. J Thromb Haemost 2010; 8: 101-6.
11. Moyer TP, O'Kane DJ, Baudhwin CM, Wiley CL, Fortini A, Fisher PK, Dupras DM, Chaudhry R, Thapa P, Zinsmeister AR, Heit JA,. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc 2009; 84: 1508-15.
12. Shelleman H, Chen J, Chen Z, Christie J, Newcomb CW, Brensinger CM, Price M, Whitehead AS, Kealey C, Thorn CF, Samaha FF, Kimmel SE,. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin Pharmocol Ther 2008; 84: 332-9.
13. The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-64.
14. Wells PS, Holbrook AM, Crowther NR, Hirsh J,. Interaction of warfarin with drugs and food. Ann Int Med 1994; 121: 676-83.
15. Fang MC, Chang R, Hylek EM, Rosand J, Greenberg SM, Go AS, Singer DE,. Advanced age, anticoagulant intensity and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Int Med 2004; 141: 745-52.
16. White RH, McKittrick T, Hutchinson R, Twitchell J,. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Int Med 1995; 122: 40-2.
17. Crowther MA, Garcia D, Ageno W, Wang L, Witt DM, Clark NP, Blostein MD, Kahn SR, Schulman S, Kovacs M, Rodger MA, Wells P, Anderson D, Ginsberg J, Selby R, Siragusa S, Silingardi M, Dowd MB, Kearon C,. Oral vitamin K effectively treats international normalized ratio (INR) values in excess of 10. Results of a prospective cohort study. Thromb Haemost 2010; 104: 118-21.
18. Weibert RT, Le DT, Kayser SR, Rapaport SI,. Connection of excessive anticoagulation with low dose oral vitamin K. Ann Int Med 1997; 125: 959-62.
19. Schulman S,. Care of patients receiving long term anticoagulant therapy. N Engl J Med 2003; 349: 675-83.
20. Makris M, Greaves M, Phillips W, Kitchen S, Rosendaal F,. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrates on correction of the coagulopathy. Thromb Haemost 1997; 77: 477-80.
21. Holland L, Warkentin TE, Refaai M, Crowther MA, Johnston MA, Sarode R,. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin dose. Transfusion 2009; 49: 1171-7.
22. Schulman S, Bijsterveld NR,. Anticoagulants and their reversal. Transfus Med Rev 2007; 21: 37-48.
23. Ozgonenel B, O'Malley B, Kristien P, Eisenbrey AB,. Warfarin reversal emerging as the major indication for fresh frozen plasma use at a tertiary hospital. Am J Hematol 2007; 82: 1091-4.
24. Hui CH, Williams I, Davis K,. Clinical audit of the use of fresh frozen plasma and platelets in a tertiary teaching hospital and the impact of a new transfusion request form. Int Med J 2005; 35: 283-8.
25. Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM,. The Warfarin Reversal Consensus Group. Warfarin reversal: consensus guidelines on behalf of the Australasian Society of Thrombosis and Haemostasis. JMA 2004; 181: 492-7.
26. Tavares M, DiQuattro P, Nolette N, Conti G, Sweeney JD,. Reduction in plasma transfusion after enforcement of transfusion guidelines. Transfusion 2011; 51: 754-61.
27. Fiore LD, Scola MA, Cantillon CE, Brophy MT,. Anaphylactoid reactions to vitamin K. J Thromb Thrombolysis 2001; 11: 175-83.
28. Whitling AM, Bussey HI, Lyons RM,. Comparing different routes and doses of phytonadione for reversing excessive anticoagulation. Arch Intern Med 1998; 158: 2136-40.
29. Watson HG, Baglin T, Laidlaw SL, Makris M, Preston FE,. A comparison of the efficacy and rate of response to oral and intravenous vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol 2001; 115: 145-9.
30. 1) in patients on long-term oral anticoagulant therapy. Mayo Clin Proc 2001; 76: 260-6.
31. Burbury KL, Milner A, Snooks B, Jupe D, Westernan DA,. Short term warfarin reversal for elective surgery-using low dose intravenous vitamin K: safe, reliable and convenient. Br J Haematol 2011; 154: 626-34.
32. th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141: 10S.
33. 1): a 5-year retrospective review. Ann Allergy Asthma Immunol 2002; 89: 400-6.
34. MacLennan S, Williamson LM,. Risks of fresh frozen plasma and platelets. J Trauma 2006; 60: S46-S50.
35. Yiu KH, Siu CW, Jim MH, Tse HF, Fan K, Chau MC, Chow WH,. Comparison of the efficacy and safety profiles of intravenous vitamin K and fresh frozen plasma as treatment of warfarin-related over-anticoagulation in patients with mechanical heart valves. Am J Cardiol 2006; 97: 409-11.
36. Malloy PC, Grassi CJ, Kundu S, Gervais DA, Miller DL, Osnis RB, Postoak DW, Rajan DK, Sacks D, Schwartzberg MS, Zuckerman DA, Cardella JF,; Standards of Practice Committee with Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Endorsement. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol 2009; 20: S240-S249.
37. College of American Pathologists. Practice parameter for the use of fresh frozen plasma, cryoprecipitate and platelets. JAMA 1994; 271: 777-81.
38. Bauer KA,. New anticoagulants. Curr Opin Hematol 2008; 15: 509-15.
39. Connolly SJ, Ezekowitz MD, Yousif S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L,; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
40. Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP,. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011; 154: 1-11.